MOUNTAIN VIEW, Calif., April 4, 2011 /PRNewswire/ — VIVUS, Inc.
(Nasdaq:
VVUS) today announced long-term data that demonstrated patients
treated with the investigational drug QNEXA® for two years
showed reductions in blood pressure and the use of antihypertensive
medications as well as improvements in lipid levels following
significant reductions in weight loss as compared to those in the
placebo group over two years.
The data – additional results from the SEQUEL study
– were presented Sunday at the 60th Annual Scientific Meeting
of The American College of Cardiology by Michael Davidson, M.D.,
clinical professor and director of preventive cardiology at The
University of Chicago.
Specific results are as follows:
- Patients on QNEXA had significant reductions in weight loss as
compared to those in the placebo group over two years.
Least-squares mean percent weight loss at week 108 was -9.3% and
-10.5%, respectively, for the mid and top dose as compared to -1.8%
for the placebo group. - Overall, patients taking QNEXA showed a significant reduction
in the number of antihypertensive medications they required as
compared to those taking a placebo over two years of
treatment. - Specifically, patients with hypertension at the beginning of
the study taking QNEXA mid and top dose showed a significant
reduction in the number of antihypertensive medications they
required of -9.8% and -18.9%, respectively, while patients taking a
placebo showed a net increase of +4.2%. - Dyslipidemic patients at baseline treated with the mid and top
dose of QNEXA had decreases in triglycerides of -25.9% and -26.3%,
respectively, as compared to -14.3% for the placebo group. - Dyslipidemic patients at baseline treated with the mid and top
dose of QNEXA had improvements in HDL-C of +11.4% and +16.7%,
respectively, as c‘/>”/>
SOURCE
